Umbilical Cord Blood Mesenchymal Stem Cells In The Treatment Of Acute Myocardial Infarction

Purpose：To study intracoronary injection of human umbilical cordblood‐derivedmesenchymal stem cells (MSCs) the efficacy of the treatment of acutemyocardial infarction (AMI).Material and method：1. Experimental study:male rats thoracotomy, ligation of the left anterior descendingcoronary artery production model of myocardial infarction was observed after24hours, survivors of myocardial infarction modeling order randomly divided intoexperimental and the control group. Isolated and cultured from human umbilical cordblood, umbilical cord blood mesenchymal stem cells, the preparation of umbilical cordblood mesenchymal stem cells (MSCs) suspension transplantation of rat myocardialinfarction model of the experimental group and control group of rats with myocardialinfarction; with PBS transplantation model. Echocardiography two sets of cardiacfunction after4weeks.2. Clinical studies: selected acute myocardial infarction and the incidence within24hours undergoing percutaneous coronary intervention therapy (PCI), umbilical cordblood mesenchymal stem cell transplantation in the treatment of patients willing toaccept a total of78cases were randomly divided into experimental group and thecontrol group,39patients. Preparation of umbilical cord blood mesenchymal stemcells (MSCs) in the suspension in AMI patients underwent PCI at the same timeattentive the catheter coronary injected MSCs suspension, for MSCs experimentalgroup. Only underwent PCI in patients with AMI, PCI control group. Patients in bothgroups after7days and90line myocardial perfusion scintigraphy andechocardiography echocardiography inspection, determination of viable myocardiumand ventricular function. Results：1. Experimental study: human umbilical cord blood detachable train the mesenchymalstem cells and cord blood derived mesenchymal stem cells were injected, and thecontrol group, the experimental rats heart function improved significantly.2. Clinical study: MSCs group90days after left ventricular ejection fraction continuedto improve, and7days after surgery and PCI control group, a significant difference.MSCs group after90days measured by SPECT myocardial perfusion defect areawas significantly lower than the PCI control group.Conclusion：1. Umbilical cord blood mesenchymal stem cell injection therapy can improve cardiacfunction in rats after myocardial infarction.2. Coronary artery umbilical cord blood mesenchymal intramyocardial transplantationof mesenchymal stem cells can be significantly improved in patients with acutemyocardial infarction, ventricular function, myocardial perfusion imaging myocardialviability increased significantly.3. Umbilical cord blood mesenchymal stem cell transplantation in the treatment ofcardiovascular disease, the effective cell cell sources.